Livagen

What is it?

Livagen is a Khavinson tetrapeptide for the liver — part of the digestive/hepatic corner of the Khavinson short-peptide bioregulator family, alongside Pancragen and Ovagen.

What does it do in my body?

Claimed mechanism: promotes chromatin decondensation in hepatocytes, reactivating silenced genes — consistent with the family’s chromatin-remodeling in-vitro line (Khavinson, Lezhava, Malinin 2004, Bull Exp Biol Med, 15085253). That study is family-wide mechanism evidence, not a Livagen-specific trial.

How can it help me?

• Where the science stands: Site tier Anecdotal (0 studies cited specifically for Livagen)

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

No adverse-event data exists for Livagen. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and Livagen’s thin published record makes it an easy target for mislabeling. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Livagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.

Typical dosing

Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.

Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.

There is no dosing or cycling data specific to Livagen — the evidence base is zero studies. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Livagen specifically.

What should I avoid combining — and what's synergistic?

Livagen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

Where do people source this?